Neurologists React to CMS' Finalized NCD Decision on Anti-Amyloid Monoclonal Antibodies for Alzheimer's Disease
/PRNewswire/ -- On April 7, 2022, CMS finalized its NCD for anti-amyloid monoclonal antibodies (mAbs) for the treatment of Alzheimer's disease. Given the...
Source: prnewswire.com